drugset / Trial / NCT02540538
Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to determine whether the HBAI20 vaccine is safe and more immunogenic than the HBVaxPro-10µg in people who have never been vaccinated with a hepatitis B vaccine and in people who have been vaccinated 6 times with hepatitis B vaccine but do not have a protective anti hepatitis B antibody titer.
Timeline
- Start
- 2015-09
- Primary completion
- 2016-07
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HBAI20 | Vaccine | — | — |
| Comparator | HBVAXPRO | Vaccine | 10 ug | — |